Oxford Cancer Biomarkers Developing CDx Biomarkers for AstraZeneca | GenomeWeb

NEW YORK (GenomeWeb News) – Companion diagnostics firm Oxford Cancer Biomarkers on Monday announced a biomarker discovery deal with AstraZeneca directed at an undisclosed drug.

Under the terms of the deal, OCB seeks to discover biomarkers that can predict responders and non-responders to the drug. OCB may also validate and further develop biomarkers resulting from the collaboration. AstraZeneca has the option to license the biomarkers.

Financial and other terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.